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Lymphatic filariasis or more commonly known as elephantiasis disease has infected 
more than 120 million people in 80 countries; and more than 40 million of them are 
unable to work, in addition to disruption of aesthetic values. The problem faced                
by almost all people in combating this infectious disease is delayed diagnosis.                
The sufferers do not realize that they have been infected with this disease.                          
A specific and accurate method of early detection is therefore needed. 99mTc-labeled 
Diethylcarbamazine-citrate (99mTc-DEC) has been successfully prepared. However, 
as part of the discovery and development of new drugs, the fulfillment of 
pharmaceutical and safety requirements have to be evaluated. Physico-chemical 
aspects such as stability, purity levels, and other pharmaceutical requirements, as 
well as pharmacokinetic studies and route of administration, are important 
parameters to be studied. The stability test showed that after seven months of 
storage, a preparation in a dry kit retains an efficiency of labeling and a purity level 
of more than 90 % and its physico-chemical and biological characteristics remained 
steady. Biodistribution test in Wistar rat showed that the greatest accumulation 
occurred in the lymphatic system, especially in the popliteal glands and in lumbar 
and mesenteric lymph nodes. Imaging with a gamma camera after intradermal and 
intravenous injections to the experimental animals resulted in a positive image that 
showed 99mTc-DEC accumulation in the target organ. The results of this innovation 
are expected to contribute significantly to improving public health, particulary in 
early detection of filarial infections. In addition, this result is expected to be a 
concrete contribution to the program of "The Global Goal of Elimination of 
Lymphatic Filariasis as a Public Health Problem by the Year 2020”. 
 
© 2017 Atom Indonesia. All rights reserved 
 
 
INTRODUCTION 
 
Filariasis or commonly known as 
elephantiasis disease is one of the diseases that 
attract particular interest from stakeholders in the 
health sector all over the world. Although it rarely 
causes death, but at its late stages, the disease can 
make a person suffer a permanent physical 
disability; thus, it has resulted in a significant 
impact especially in the community of developing 
countries, either in the tropics or subtropics, that are 
suffering social-economic problems [1].  
                                                 
Corresponding author. 
  E-mail address: evamaria@batan.go.id,  
          d_setiawan@batan.go.id 
  DOI: https://doi.org/10.17146/aij.2017.747 
Lymphatic filariasis (LF) is one of the major 
causes of acute and chronic morbidity that affect the 
population of tropical and subtropical areas of Asia, 
Africa, Western Pacific, and several regions of the 
Americas. It is estimated that over 1.2 billion people 
live in areas at risk of the disease, and among the 
120 million actual cases, 91 % are caused by the 
worm Wuchereria bancrofti [2,3]. It was recently 
reported that more than one billion people in the 
world are at risk of suffering of filariasis. More than 
120 million people from 80 countries have been 
infected by microfilaria; the disease was even 
declared endemic in thousands of villages in                   
26 provinces in Indonesia. These are the reasons                
the World Health Organisation (WHO) declared a 
global agreement to combat this disease with the 
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theme of the Global Goal of Elimination of 
Lymphatic Filariasis as a Public Health Problem by 
the Year 2020 [4]. 
Detection of filarial worms depends on the 
presence of microfilariae in the peripheral blood 
stage, or is known as periodicity stage. Interestingly, 
filarial periodicity is found in between 10 pm and                
2 am (nocturnal). Therefore, blood sampling should 
be done at night. In addition, the active larvae can 
only be discovered 6-12 months after a person                
has been infected with filaria, and the manifestations 
of filariasis only become visible after around                 
four years. Therefore, early detection for this case    
is quite difficult to attain. Laboratory tests for 
identification of filarial antigens by enzyme-linked 
immunosorbent assay (ELISA) technique or rapid 
immunochromatographic card can actually be                
done, but those techniques are complicated and 
often give false positive results [5-12]. Diagnosis 
techniques with higher sensitivity and specificity are 
still needed . 
Nuclear medical techniques using 
radiopharmaceuticals provide an alternative 
approach to solve this problem. Diethylcarbamazine 
citrate (DEC) is a drug for the treatment of filariasis 
in humans and animals (Fig. 1). DEC has had a long 
history of safe use in mass drug administration 
(MDA) lymphatic filariasis eradication program. 
Furthermore, W. bancrofti, the human parasitic 
roundworm that causes lymphatic filariasis,                      
do not appear to have developed resistance to DEC 
[13-15]. We hypothesized that DEC could be 
labeled with radionuclide technetium-99m (99mTc)   
to form the organometal complexes of 99mTc-DEC. 
The 99mTc-DEC radiopharmaceutical is expected to 
be uptaken by microfilariae in the body of an 
infected person due to binding between 99mTc-DEC 
and the filariae’s DEC receptor. Thus, the presence 
of microfilariae in the body can be detected 
externally by gamma camera; therefore, the early 
detection of filariasis can be established. 
 
 
 
    
Fig. 1. Chemical structure of DEC. 
 
The working targets of DEC are arachidonic 
acid (arachidonate 5-lipozygenase) and 
cyclooxygenase pathway (cytochrome-C-oxydase 
subunit-1) located on microfilaria sheaths.                    
DEC mechanism as an antifilarial parasite is 
estimated to be reduction of muscle activity causing 
the filaria to be paralyzed and easily moved out 
from the host [13,16]. Another suggestion is that 
DEC may cause changes in microfilaria membrane 
surface, so it is more easily destroyed by the host 
defense system. This mechanism of action is 
hypothesized to be identical when 99mTc-labeled 
DEC is used as a diagnostic agent. The imaging 
process of 99mTc-DEC bound to microfilariae will 
easily be done from outside the body as a result of 
gamma radiation emitted from the technetium-99m 
that is attached to the DEC. Therefore, the presence 
of microfilariae in the body can be detected 
precisely and accurately anytime and anywhere. 
The formulation and preparation of 99mTc-
DEC radiopharmaceutical dry kit had been 
conducted in the previous research [17]. The kit’s 
labeling efficiency and radiochemical purity was 
higher than 95 %, and its physico-chemical 
characteristics were good. However, the results of 
the aforementioned research could not be applied 
clinically when several pharmaceutical and safety 
testing requirements had not been carried out. 
Therefore, various other parameters, such as 
biological, pharmacological, and toxicological 
aspects, as well as dose conformity and route of 
administration, have also to be studied. It is 
important to verify the uptake of 99mTc-DEC by 
filaria. The verification could not be done only 
through in-vitro studies, but must also be 
accompanied by in-vivo testing in animals infected 
with filaria.  
Therefore, the objectives of this research were 
to obtain data which indicate that 99mTc-DEC meets 
pharmaceutical requirements, and to convince 
potential users (end user) that the resulting               
formula can be used as a diagnostic agent for early 
detection of filariasis. The use of this new 
radiopharmaceutical is expected to give a real 
contribution in solving the present problem of 
filariasis infection of the Indonesian community. 
This in turn will support the Global Goal of 
Elimination of Lymphatic Filariasis as a Public 
Health Problem by the Year 2020 program                         
in particular and the Indonesian health program                 
in general. 
 
 
EXPERIMENTAL METHODS 
 
Radiolabeling and stability study of 
99mTc-DEC  
 
The labeling of DEC with 99mTc was 
conducted using a direct method. Two forms 
consisted of 4 mg DEC-citrate and 100 mg 
SnCl2.2H2O, pH 4 were prepared. The first formula 
was freshly prepared and the second one was freeze 
dried and re-constituted just prior addition of 99mTc. 
Labeling of DEC with 99mTc was performed by 
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adding an aliquot of 99mTc-pertechnetate into                 
the aforementionrd forms followed by incubation              
at room temperature for 10-20 minutes. The results 
of radiolabelling, which is stated as radiochemical 
purity, was determined using two-system 
chromatography. The first system was 
chromatography using Whatman 3MM paper                
(1×10 cm) as stationary phase and dry aceton                 
as mobile phase. This system was for separating 
99mTc-DEC from free 99mTc in form of 99mTc-
pertechnetate (99mTcO4-). The second system was 
chromatography using ITLC-SA (1×10 cm)                         
as stationary phase and water as mobile phase.                  
This system was created for separating 99mTc-DEC 
from free 99mTc in its reduced form (TcO2).                      
The labeling radiochemical purity of 99mTc-DEC can 
be calculated with eq. (1): 
 
Labeling Efficiency = 100% - (% 99mTcO4 + % 99mTc-red)  (1) 
 
The stability of 99mTc-DEC (indicated as 
radiochemichal purity) after storage at certain 
periode of time was tested with the aforementioned 
chromatograph. Stability test of freeze dried 
DEC/DEC kit over certain period of time                   
during seven months of storage was also performed. 
The stability is considered good when labeling 
efficiency and purity level are both higher than                   
90 %, and there are no changes in physico-chemical 
and biological performance during storage. The test 
was performed in a similar manner to the 
radiolabeling procedure as previously mentioned, 
followed by radiochemical purity determination.  
 
 
Biological evaluation 
 
Biological tests on animal were conducted 
after obtaining approval letter No. 
001/KEPPHP/BATAN/III/2012 dated March 20, 
2012 from the Animal Ethics Committee (KEPPHP-
BATAN). 
 
 
Sterility test of DEC kits 
 
The sterility test was performed according to 
the procedure in Indonesian Pharmacopoeia and 
published journal papers using two types of media, 
namely the Fluid Thioglycolate Medium (FTM) for 
aerobic and anaerobic bacteria and the Soybean 
Casein Digest Medium (SCDM) for fungus/mold 
[18]. Two vial DEC kits (one batch consists of               
25 DEC kits) were reconstituted with one mL of 
saline solution. Each solution was then added into 
glass tubes containing 5 mL of FTM or 5 mL of 
SCDM respectively. FTM tubes were incubated in 
the incubator (37 °C), and SCDM tubes were placed 
at room temperature (25-27 °C). Media tubes were 
observed for up to 14 days; if there was no growth 
of bacteria or mold colonies, then the DEC kit                
was sterile. However, if there was a growth of 
bacteria or mold, as indicated by the formation of 
cloudy areas or colonies in the media, experiments 
should be repeated with twice the number of 
samples (four vials of  DEC kits), and if after                    
14 days of observation growth of colonies of 
bacteria or mold was still found, the DEC kits were 
not sterile.
 
 
Pyrogenity test of DEC kits 
 
 The pyrogenity test of 99mTc–DEC was 
conducted in accordance with the methods and 
procedures in Indonesian Pharmacopoeia [18] using 
three white rabbits (2-3 Kg). The rabbits’ body 
temperatures were recorded at 30 minutes before the 
injection of radiopharmaceuticals as the initial 
temperature. Afterward, 500 µL of 99mTc-DEC was 
injected intravenously through the auricular vein in 
each rabbit's ear at minute 0. The body temperatures 
of the rabbits were measured again after one, two, 
and three hours after injection. The highest 
temperature obtained from the 1 hour until the                 
3 hour after injection is called the maximum 
temperature. The 99mTc-DEC was declared pyrogen-
free if the rise in body temperature of the rabbit after 
injection was not greater than 0.5 °C. 
 
 
Acute toxicity determination 
 
The acute toxicity determination of                    
99mTc-DEC was conducted in accordance with                
the methods and procedures in Indonesian 
Pharmacopoeia with a slight modification [19] by 
multiplying certain number of dose given to the test 
animals (Swiss mice) after converted into common 
dose received by humans. Each treatment was 
carried out on five mice. 99mTc-DEC was injected 
intradermally and intravenously at a dose which  
was increased gradually. Test animals were 
observed daily for up to 14 days, and if there were 
physical abnormalities or abnormal movements, the                   
99mTc-DEC was declared toxic. 
 
 
Biodistribution of 99mTc-DEC 
 
Induction of microfilariae into experimental rats 
 
Figures 2(a) to 2(e) show the sequence of 
events of induction activities through the injection 
of the blood from patients infected by microfilariae 
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to the test animals in the middle of the night (after 
22:00 pm). Blood samples from five filarial 
volunteers (Fig. 2(b)) were collected and 1 mL was 
injected to 10 experimental Wistar rats (250-300 g) 
on the same day (Fig. 2(e)). The remain blood 
samples were analyzed in the laboratory with a 
Nikon microscope (Fig. 2(c)) and Fig. 1(d)).  
 
 
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
 
 
 
 
 
 
 
 
(e) 
 
Fig. 2. Sampling of filarial perifer blood (a); blood analysis         
(b & c); microscopic image of microfilaria in the blood (d);  
injection of  infectious blood into rats Wistar (e). 
 
All injected experimental rats were 
maintained for several months with a special 
treatment. The conditions of those animals were 
observed every day and blood samples were taken 
and analyzed at certain times by using microscope 
to see if there has been a growth of microfilariae. 
 
 
Biodistribution study of  99mTc-DEC 
 
Three months post infection, three 
experimental rats were injected intravenously with   
1 mL of 1-mCi/mL 99mTc-DEC, and three others        
were injected intradermally with 0.1 mL of                
the same activity concentration of 99mTc-DEC. After               
15 minutes post injection, the rats were anesthetized 
by ketamine solution injection to death, followed by 
dissection. Several critical organs were taken, and 
the radioactivity accumulation of 99mTc-DEC was 
determined by using a single channel analyzer.  
 
 
Determination of the kinetic profile 
99mTc-DEC 
 
The determination of the kinetic profile in test 
animals was done to three normal and three infected 
Wistar rats. The injection dose was similar                   
to the dose used in the biodistribution study.          
After intradermal and intravenous administration of 
99mTc-DEC, blood samples were taken from tail vein 
of each rat at the times of 5, 15, 30, 45, 60, 120, and 
180 minutes post injection. Blood samples             
were weighed and their radioactivities measured 
with a single channel analyzer. The biological          
half-life was then calculated from the kinetic        
profile of 99mTc-DEC by using computerized 
Multivit program.  
 
 
Gamma camera imaging 
 
Imaging was performed with a gamma 
camera (GE Infinia-Hawkeye SPECT/CT) on 
normal and filarial-infected Wistar rats after 
injection of 0.1 mCi (0.1 mL) of 99mTc-DEC 
intradermally and intravenouslly. 
 
 
RESULTS AND DISCUSSION 
 
Figure 3 shows DEC kits that had been 
cprepared and was used throughout this research. 
These kits are easily distributed to nuclear medicine 
departments in hospitals for prepariation of the 
99mTc-DEC radiopharmaceutical. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. DEC kits. 
 
The stability of the DEC kits is indicated by 
the absence of physical changes during storage, as 
well as by the labeling efficiency and radiochemical 
purity level of no less than 90 %. The labeling 
efficiency and radiochemical purity level of the kit 
used, during the time period of storage in the 
refrigerator, is shown in Table 1. 
DEC dried-kit 
vials 
Brochures 
Radioactive 
labels 
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Table 1. Labeling efficiency and radiochemical purity levels 
during the storage of the DEC kits labelled with 99mTc 
 
No. Storage Time 
(months) 
Labeling Efficiency and 
Radiochemical Purity  (%) 
1. 0 95.4 ± 3.3 
2. 1 97.2 ± 0.8 
3. 2 98.3 ± 0.2 
4. 3 98.3 ± 0.4 
5. 4 96.4 ± 1.3 
6. 5 97.3 ± 0.5 
7. 6 98.0 ± 0.0 
8. 7 98.2 ± 0.8 
 
Table 1 shows that labeling efficiency and 
radiochemical purity of DEC kits (stored for up           
7 month) labeled with 99mTc were higher than 90 %. 
This indicates that the DEC kits were stable during 
this storage period. When compared with 
ciprofloxacin kits that are stable in storage for up to 
17 weeks [20], the DEC kits were more stable. 
The stability of DEC kit labeled with 99mTc 
(99mTc-DEC) under up to four hours of storage is 
shown in Table 2. This result show that for up            
to two hours of storage, the 99mTc-DEC still had          
an acceptable radiochemical purity (> 90 %).            
The decrease of radiopharmaceutical purity levels of 
99mTc-DEC during storage might be caused by 
radiolysis or by conformation of the 99mTc-DEC 
complex itself. However, compared with 99mTc-
ciprofloxacin radiopharmaceuticals, this 99mTc-DEC 
complex was more stable. The radiochemichal 
purity of 99mTc-ciprofloxacin for just 45 minutes of 
storage is not acceptable (< 90 %) [20]. 
 
Table 2. Effect of solution storage after addition of 99mTcO4-  
 
Stability after reconstitution with Sodium 99mTc–pertechnetate 
solution 
Storage period at 
room temperature (h) 
1 2 3 4 
Yield or radiochemical 
purity (%) 
96.31 90.48 88.90 87.16 
 
Considering the data in Table 2, the user 
should not keep 99mTc-DEC for too long or us it for 
more than two hours when it is reconstituted with a 
solution of sodium pertechnetate-99m. 
The pyrogenity and sterility test of             
99mTc-DEC made afresh (recentus paratus) or from 
a kit from that had been stored up to eight months 
found it sterile and pyrogen-free.  
On the other hand, because the injection 
volume should be as small as possible, the amount 
of sodium pertechnetate added must be as 
concentrated as possible. There has been a concern 
that radiolabeling of DEC with a large volume of 
99mTc-pertechnetate might hinder the radiolabeling 
process. Therefore, radiolabeling of DEC with 
99mTc-pertechnetate with volume range of 1-4 mL 
was carried out. Table 3 shows that the volume          
of 99mTc-pertechnetate slightly influenced the 
radiolabeling efficiency of DEC. It can been seen 
that radiolabeling with 99mTc-pertechnetate volumes 
larger than 1 mL decreased the radiolabeling 
efficiency to 92.23-94.58 %. However, these              
results still met the requirement through its average 
value of 94.65 ± 2.38 %.  
 
Table 3. Effect of  volume 99mTc-pertechnetate on DEC 
labeling 
 
Volume of 99mTc-
pertechnetate (ml) 
Labeling Efficiency 
(%) 
1.0 97.90 
2.0 92.23 
3.0 93.89 
4.0 94.58 
 
The acute toxicity test was conducted by the 
administration of 99mTc-DEC through two routes of 
injection, namely intradermal and intravenous 
injections. Observations were carried out for seven 
days and can be continued to up to 14 days in order 
to notice if there were abnormalities that may occur. 
The results of the toxicity tests are shown in         
Table 4. The data show that there was no 
abnormalities or death on test mice despite being 
given doses much higher than that expected to be 
used for humans. According the test data on acute 
toxicity, it can be stated that the 99mTc-DEC is safe 
to be used. 
 
Table 4. Observations acute toxicity tests of 99mTc-DEC on test 
animals 
 
Injection 
routes 
Weight of 
mice (gram) 
Dose of  
 99mTc-DEC 
Human 
Conversion 
dose 
Abnormalities 
during 7-14 
days of 
observation 
 intradermal 30.4 ± 2.70 462 µCi  
(15.2mCi/kg) 
 
912 x 
 
- 
 intravenous 38.0 ± 1.97 430 µCi  
(11.3mCi/kg) 
 
135 x 
 
- 
 
The biodistribution data displayed in Fig. 4 
showed that at 15 minutes after intradermal 
injection the highest accumulation of radioactivity 
was found in the popliteal lymph nodes (27.5 %);         
it decreased to 4.76 % at 120 minutes after injection. 
 Accumulation was also found in several other 
lymphatic organs such as lumbar and mesenteric 
lymph nodes. Significant radioactivity was also 
found accumulating in the kidneys. This can                    
be understood as the kidney is a main excretory 
organ and 99mTc-DEC is polar compound.                     
This biodistribution data indicates that 99mTc-DEC 
can reach the target organ. 
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Fig. 4. Biodistribution of 99mTc-DEC in rat after intradermal 
injection. 
 
Although the highest uptake of radioactivity 
was found in the popliteal lymph nodes at the 
beginning of injection as shown in Fig. 5, but the 
sharp decline occurred at minute 45 when compared 
with the lumbar and mesenteric nodes. This was 
possibly because the popliteal nodes are closer to 
the area of injection compared with lumbar and 
mesenteric nodes. Then, after decreasing, the 
accumulation of radioactivity rose in similar pattern 
for all of three lymphatic glands. 
 
 
 
Fig. 5. Lymphatically uptake of  99mTc-DEC.  
 
A pharmacokinetic study was performed by 
injection of 99mTc-DEC through intradermal and 
intravenous routes in normal mice and infected 
mice. Blood samples were collected from the mice 
tails at 5, 15, 30, 45, 60, 90, 120, and 180 minutes 
after injection. The blood samples were weighed 
and measured using a single channel analyzer 
(ORTEC 4890), and the calculation of 
radioactivities were corrected to the half-life (t½) of 
99mTc. Activity concentration in blood from the 
intradermal route of injection as a function of time 
is shown in Fig. 6. 
Assuming that 99mTc-DEC was in one 
biocompartment, the value of biological half-life 
after intradermal injection in normal mice obtained 
at 44.32 minutes (Fig. 6(a)), whereas in infected 
mice by 37.83 minutes (Fig. 6(b)). By considering 
the individual characteristics of living creatures, 
these values did not show a significant difference. 
Therefore, the biological half-life can be expressed 
as approximately 40 minutes. The 99mTc-DEC that 
was administered via intradermal injection seemed 
to have a relatively longer biological half-life.  
 
 
 
Kinetic profile of 99mTc-DEC through intradermal administration in 
normal mice t½ distribution = 4 minutes, 
and t½ elimination = 44.32 minutes 
(a) 
 
 
 
Kinetic profile of 99mTc-DEC through intradermal administration in 
infected mice t½ distribution = 10.49 minutes, and 
t½ elimination = 37.83 minutes 
(b) 
 
Fig. 6. Pharmacokinetic profile (intradermal route injection) of 
99mTc-DEC in normal mice (a) and infected mice (b). 
 
This indicated that 99mTc-DEC was retained in the 
body for a significant duration. On one hand, this 
provides a distinct advantage because the 
lymphoscintigraphy technique for detecting 
filariasis also takes a long time, so there is flexibility 
for physicians to perform diagnostic management. 
On the other hand, administration via intradermal 
injection would cause difficulties in distinguishing 
between the physical blockage or obstruction of 
infections caused by microfilariae through 
lymphoscintigraphy techniques; consequently, 
administration through intravenous injection 
becomes the preferred technique.  
Figure 7 indicates that the biological half-life 
in one compartment model with intravenous 
injection give the value of 29.7 minutes. This value 
was sufficient to discover the uptake of 99mTc-DEC 
in the body when an imaging was performed a using 
a gamma camera. 
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Fig. 7. Kinetic profile of 99mTc-DEC after intravenous injection. 
 
Imaging with a gamma camera can be used as 
key evidence to indicate that this agent is acceptable 
for use. Imaging is intended to ensure that this agent 
accumulates in the target organ. Figure 8 (a and b) 
shows the result of gamma camera imaging                   
after intravenous and intradermal administration of 
99mTc-DEC in rat infected with filariae.  
 
 
 
 
(a) 
 
 
 
(b) 
 
Fig. 8. Imaging in rat infected with filarial with 99mTc-DEC 
intradermally (a) and intravenously (b). 
While gamma camera imaging results as 
displayed in Fig. 8(a) and 8(b) show 99mTc-DEC 
distributed in several organs of the rat, the 
evaluation is still difficult. The presence of 
blackening in the intestine after intravenous 
injection also gives doubt to determination if the 
abnormalities are caused by filariae. This is possible 
because the rodent’s body is too small. Therefore, 
the final verification as an evidence for the solution 
should be performed on voluntary patients              
with filariae. 
 
 
Potential development for the future 
 
Given the large number of filariasis cases found, it 
is hoped that this diagnostic agent can be 
immediately utilized. The preparation and analysis 
technology has been owned and mastered. Potential 
development is possible to follow up. Clinical 
evaluation of 99mTc-DEC to filarial patiens is                     
very important and absolutely must be done.                      
The diffusion of technology and the development of 
science and technology capacity of the production 
system is expected to accelerate. 
 
 
CONCLUSION 
 
Diagnostic kits of DEC in a freeze dried and 
sterile form have been succesfully formulated and 
ready to be labeled with 99mTc to produce 99mTc-
DEC for diagnosis filariasis infection. In-vitro                 
and in-vivo evaluations such as testing stability of 
99mTc-DEC, biodistribustion, pharmacokinetic, and 
toxicological studies which have been conducted 
and showed very promising results. 
In a new drug development, there are many 
requirements that must still be met prior to use by 
the public, especially the completion of the 
preclinical and clinical data, particularly in 
voluntary patients with filariae. 
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